Trials / Completed
CompletedNCT00547287
Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across Nations
Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Multinational Assessment of Treatment Preference
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,760 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study to determine if men from around the world prefer sildenafil to tadalafil.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tadalafil | 20 mg tadalafil as needed by mouth no more than once a day for a 4 week initiation period and a 4 weeks treatment period. |
| DRUG | sildenafil | Current dosage of sildenafil is continued for 4 weeks (no more than once a day) of treatment assessment then the wash-out period will begin. |
Timeline
- Start date
- 2002-11-01
- Completion
- 2004-05-01
- First posted
- 2007-10-22
- Last updated
- 2007-10-22
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT00547287. Inclusion in this directory is not an endorsement.